Ribavirin antagonizes the effect of azidothymidine on HIV replication
about
Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermineDebio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitorsFast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C.Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical studyRibavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of ValopicitabineTherapeutic issues in HIV/HCV-coinfected patientsCoinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical OutcomesRibavirin--current status of a broad spectrum antiviral agentPeginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected personsAnti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cellsSynergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidineSynergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitroCombinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidineInhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnetStructure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virusRibavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitroSynergistic and antagonistic drug combinations depend on network topologyChallenges in the treatment of HIV and HCV coinfection.Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.Treatment of human immunodeficiency virus infectionsAbacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infectionsVaccine and antiviral strategies against infections caused by human immunodeficiency virus.Coinfection with HIV and HCV: more questions than answers?Human immunodeficiency virus-hepatitis C coinfection: swapping new problems for newer ones.3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replicationHepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy.Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients.Hepatitis C and human immunodeficiency virus infection.Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development.Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy.Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.Antiviral therapy for human immunodeficiency virus infectionsSafety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.Update on Hepatitis C Virus and HIV Coinfection.Strategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy.
P2860
Q24633025-E4E1DF7E-4004-4C77-BE45-80165B2C2F14Q24645702-8FC71D77-E6D4-43CF-AF78-815E5645E009Q24804388-EA247B3E-E717-4B58-A191-D2B564524CA0Q27472607-E4866688-19CF-4E0F-AA47-7C5400ECAFEFQ27477522-03F6C21E-D6CE-443F-A58B-2DB69D47561AQ27481053-478A40E4-5E97-4277-A9CC-071811483D11Q27488883-0C172862-A59F-4001-8A94-153069EDD366Q28190105-EEE50639-21E8-4ADA-BD3F-0222B097CF40Q28274676-D8FDAB76-696C-4038-BC65-D1CA818380AAQ28323830-D27A2DD5-18B3-4568-8E6E-BEED588A0F12Q28324208-828BE115-9495-46D1-8069-FF3F3B0C208DQ28333682-EA1554A0-313E-4161-BB4F-F6C972E31300Q28339702-166EF0F3-3F04-4D43-99A5-DE8D5129DE4AQ28340298-A3F662C8-3B9F-4A60-AF01-5622B6EE80D0Q28341972-7FAD4469-87DF-4B15-8627-149ECB6CE489Q28342189-F4A11EA4-7FC1-4494-9CDB-64022B9753C3Q28359820-6036013C-1C7E-4237-A60E-FFF642A14BC6Q28361577-B63FC83C-A4CA-4794-B066-B2A66861D209Q28542101-033450E7-F6E2-487B-B81B-B2D6A0A15976Q30389282-94408F90-B3EB-4AD2-BE00-909DF68F5E8BQ31975873-75DCE633-8ACE-4E1B-BC0E-99437FF117ECQ33740357-8E30B143-F943-4F11-8B43-6F4F9581937AQ33906382-7A82C1E1-F696-49CA-94EC-CB2B5E9E9FA7Q33999381-AFCD1FAC-842F-4FCB-BA18-2EFE03A8C883Q34101462-D7478B2B-1D7A-4D36-A44B-693441C5E6E2Q34113786-DC3F4887-E804-4EB7-AE39-3BAC1E14C01BQ34390060-2D8ECFAF-074E-41A0-B240-1C61B30FDDA2Q34440411-E40DF289-DC18-4780-9027-C85C2FB316B6Q34536150-666543C1-7C13-4D92-8C8D-CDE267D8D828Q34631679-A95CEA79-F807-4515-8250-A0ADBE3E92B5Q34984125-8B44FCDF-6EC9-479A-9242-0FFC7DAB147BQ35174403-50F4B9C9-3EDD-4B4B-860C-93EB9111E879Q35232016-DBB221F9-4166-45D4-86AE-DEFF3D7005DEQ35325810-92B2FA16-6D7D-4404-BCC2-1F6AD682D8CEQ35362117-1F595D00-F495-44E7-B2C3-1A1A13BB945BQ35366050-D7780176-47C2-4B5E-B4A5-2A8BC44BE4EFQ35810419-67191BCE-B6A6-4E9E-940D-9C6C9EE86900Q35836636-1907DEFE-A8E4-4563-A055-FE84AF03F951Q35906047-229864E8-AC82-4082-BC88-BE67A81275AAQ35930774-1F982956-7BC6-40F3-A9F4-8201BEA157C1
P2860
Ribavirin antagonizes the effect of azidothymidine on HIV replication
description
1987 nî lūn-bûn
@nan
1987 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի մարտին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@ast
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@en
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@nl
type
label
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@ast
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@en
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@nl
prefLabel
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@ast
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@en
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@nl
P2093
P2860
P356
P1433
P1476
Ribavirin antagonizes the effect of azidothymidine on HIV replication
@en
P2093
C Crumpacker
K L Hartshorn
L A Coleman
M S Hirsch
P A Furman
R T Schooley
P2860
P304
P356
10.1126/SCIENCE.2435003
P407
P577
1987-03-13T00:00:00Z